SALT LAKE CITY, April 25, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Christine Seward, MS, CGC, has joined Predictive Laboratories as Senior Vice President of Sales and Marketing. Ms. Seward brings extensive experience commercializing molecular diagnostics including products in the reproductive space from her 16-year tenure at Myriad Genetics.
Predictive Laboratories also announces the appointments of Lesa Nelson as Chief Operations Officer and Debbie Dyckman as Director of Quality Assurance of Predictive Laboratories. Both Ms. Nelson and Ms. Dyckman previously served in the same capacity at Taueret Laboratories, which was acquired by Predictive in March 2019. Ms. Nelson, who has 27 years in human genetic research including more than 20 years in senior management positions, directs all operational activities and serves as the laboratory Technical Supervisor at Predictive Laboratories. Ms. Dyckman has more than 15 years of experience in clinical trials research and quality assurance and is responsible for licensing, accreditation, document control, lab safety, internal and external inspections, quality assurance reviews and audits, and CAPA management at Predictive Laboratories.
“We are delighted to attract these highly qualified professionals as we expand our genetic testing capabilities with an initial focus on human infertility and women's health,” said Bradley Robinson, CEO of Predictive Technology Group. “Christine is highly accomplished in driving the commercial growth of molecular diagnostics with a history of successfully developing and executing product launches and negotiating contracts that exceeded growth targets. Lesa and Debbie have worked with Predictive through our prior relationship with Taueret Laboratories and bring direct, proven expertise that will be invaluable in the expansion of our state-of-the-art laboratory operations.”
Ms. Seward served in various positions with increasing responsibility at Myriad Genetics, most recently as Senior Strategic Product Director – Payer Markets. In this position, she was responsible for collaborating and aligning with a cross-functional team to develop peer-reviewed publications and developing innovative study designs to demonstrate the clinical validity, utility and cost-effectiveness of Myriad products including for reproductive health. Among prior positions at Myriad, she served as Director of Elevate 2020; Director of Marketing, Oncology Biomarkers; Senior Sales Representation; and Medical Specialist. Prior to joining Myriad, Ms. Seward was an oncology genetic counselor at the University of Virginia Health System. Ms. Seward received a Master of Science in Genetic Counseling from California State University, Northridge, and is board certified by the American Board of Genetic Counseling.
Ms. Nelson previously was Vice President of Clinical Operations for Axial, Biotech, Inc., a company focused on developing and commercializing genetic tests and treatment solutions for spinal disorders. Ms. Nelson is an active member of the American Association of Human Genetics (ASHG), the American Association of Blood Banks (AABB) and the Association of Molecular Pathologists (AMP). She has authored or co-authored more than 40 human genetics-related articles and scientific papers published in various peer-reviewed medical periodicals, and is a named inventor in three U.S. patents and five published U.S. patent applications related to the diagnosis and prognosis of human genetic conditions.
Ms. Dyckman previously served as Quality Assurance Supervisor at Affiliated Genetic and at Axial Biotech. In these prior positions, she was responsible for controlling standard operating procedures, and managing licenses and accreditations. Before that she was a Site Start-up Specialist at Quintiles (now IQVIA), where she was responsible for negotiating contracts and budgets, and guiding sites through their scientific review and approval processes. She graduated from the Medical Technology Program at Utah State University, the Lab Tech program at Claremont Mesa College and the Clinical Trial Research – AAS program at Durham Technical Community College.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide™, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit to www.predtechgroup.com or contact Investor Relations:
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
